Ingo Schwaner

Suggest Changes
Learn More
BACKGROUND Gemcitabine usually given until progressive disease (PD) is the main first-line treatment option for patients with inoperable advanced pancreatic cancer (APC). Currently there is no(More)
PURPOSE To assess the efficacy of a second-line regimen of oxaliplatin and folinic acid-modulated fluorouracil in patients with advanced pancreatic cancer who have experienced progression while(More)
PURPOSE To identify predictive factors for a good leukapheresis yield and to determine peripheral-blood progenitor cell (PBPC) dose requirements for rapid hematopoietic engraftment. PATIENTS AND(More)
Patients with relapsed or refractory non-Hodgkin’s lymphomas (NHL) and Hodgkin’s disease (HD) with recurrences after an anthracyclin-containing regimen only have a chance of cure of below 10% with(More)
  • 1